Clinical Trials

Participation in clinical trials and research is the only way we can hope to find cures for diseases such as Alzheimer's disease, and promote normal healthy brain and body aging for all!

ADCS CLINICAL TRIALS - Sponsored by the National Institutes of Health (NIH) / National Institute of Aging (NIA)

These research opportunities are sponsored by the Alzheimer Disease Cooperative Study Group, and are currently recruiting at the UK-ADC and the Sanders-Brown Center on Aging.

Alzheimer’s Disease Neuroimaging Initiative Grand Opportunity (ADNI GO) Study

Building on the momentum of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), this study focuses on participants with early mild cognitive impairment (eMCI) to help researchers more fully understand Alzheimer’s disease progression in its earliest stages. For more information click here or call Sarah at (859) 323-1331.

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity (ADNI 2)

Building on the momentum of the previous phases of the Alzheimer’s Disease Neuroimaging Initiative (ADNI), this study focuses on participants with early mild cognitive impairment, late mild cognitive impairment, early to moderate Alzheimer’s disease and people with no memory complaints. For more information click here or contact Barbara Martin (859) 323-0494, barbara.martin@uky.edu.

UK-ADC Industry-Sponsored Clinical Trials

Research Opportunities Conducted in Collaboration with Pharmaceutical Industry Partners and the UK Alzheimer's Disease Center / Sanders-Brown Center on Aging.

Many exciting and potentially important breakthroughs in the field of Alzheimer’s disease have come from pharmaceutical industry initiatives and discoveries. While the UK-ADC and the SBCoA are supported solely through Federal, State, and private funds, we realize that many important drug discoveries that may lead to the eventual development of a cure for Alzheimer’s disease and other related disorders are highly dependent on the research and development of drugs by private, for-profit, pharmaceutical industry sponsors. Such developments are dependent on engagement by non-profit organizations such as ours if we all hope to move forward towards a cure in as fast a timeline as possible. Participating in clinical trials of investigational agents that hold great promise allows you and your loved ones to more fully engage in the battle against AD and open doors to research participation with investigational compounds you might otherwise not have access to.

To accomplish these goals we pledge to:

Remain independent from all for-profit motivations from any and all affiliated research groups
Never use Federal, State, or privately donated resources to further for-profit discoveries in the area of AD research
Recycle all excess funding that pays for completion of clinical trial activities into the community for education, outreach, caregiver and patient support that would otherwise never be funded or accomplished.
Rigorously scrutinize every request for clinical trial participation to ensure that risks, benefits, and potential gains to the field outweigh any private, for-profit interests of the pharmaceutical partners we may engage with in order to move the field closer to a cure for AD and related disorders.

This pledge is our promise to you that our research motivations and ethical standards will always place you and your loved ones first!

Industry Sponsored Trial Open for Enrollment

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION^TM) as a Useful Cognitive Biomarker for Alzheimer's Disease

The primary goal of this study will be to evaluate the COGNISION™ platform across multiple study locations. This will demonstrate an ability to perform tests, collect data, and generate classifications irrespective of variations in testing locations and personnel. For more information click here or contact Melinda Dowden-Kruger (859-323-2093) melinda.dowden-kruger@uky.edu

Study Evaluating the Long-Term Safety and Efficacy of Subcutaneous Bapineuzumab

Subcutaneous injections of Bapineuzumab may make this compound as easy to use as daily insulin injections for a diabetic. Previous studies have relied on intravenous infusions that require visiting a medical center to receive this experimental compound. Researchers hope that self administration of this agent may remove toxic proteins from the brain in Alzheimer’s disease and make the use of this medicine practical for the over 5 million Americans afflicted with this devastating disease.

For more information click here or call Sarah at (859) 323-1331.

Ongoing Studies Closed for Enrollment

Gammaglobulin Alzheimer’s Partnership (GAP/IVIg) Study

Intravenous Immune Globulin (IVIg) has been approved and used successfully for over 20 years to treat a variety of autoimmune and immunodeficient diseases. Because it contains anti-amyloid antibodies, IVIg is being investigated in a Phase III study as a treatment for Alzheimer's disease. Click here for more information

Home-Based Assessments (HBA) Study

This study is evaluating three methods of performing home-based assessments in an Alzheimer's Disease (AD) prevention trial. Click here for more information

Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE)

The Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) prevention trial is an important addition to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). As a prevention trial, PREADVISE is trying to find out if taking selenium and/or Vitamin E supplements can help to prevent memory loss and dementia such as Alzheimer's disease. Click here for more information.

Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)

This is a multicenter, double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 200 study sites in the US and Canada will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. For more information click here or call Sarah at (859) 323-1331.

Bapineuzumab in Patients with Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)

This is a multicenter, double-blind, placebo controlled, randomized, outpatient multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD. Approximately 230 study sites in the US and Canada and up to 35 sites outside of North America will be involved. Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years. For more information click here or call Sarah at (859) 323-1331.

RAGE Inhibitor (RI) Study

Researchers are participating in a new nationwide study that will test an experimental treatment to target the source of the disease. The experimental drug may block a critical pathway in AD that causes damage to the nerve cells in the brain. Participants will receive either the active study drug or placebo (inactive pill). All participants will be monitored carefully by a team of doctors and nurses at the research clinic throughout the study. Click here for more information.

Dimebon (latrepirdine)

Medivation, in collaboration with Pfizer, is currently evaluating dimebon in both Alzheimer’s and Huntington diseases. The Phase 3 CONCERT study, which has completed enrollment, is evaluating dimebon in patients already treated with donepezil, the leading Alzheimer’s disease medication worldwide.